NCT06489756Completed
Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)
Effect of Supplemental Oxygen Therapy (SOT) on Pulmonary Arterial Pressure in Highlanders With High Altitude Pulmonary Hypertension Permanently Living at >2500m
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension (HAPH) who permanently live \>2500m on pulmonary arterial pressure (PAP) assessed at 3200 m.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 28 Jun 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- University of Zurich
- NCT number
- NCT06489756
What you commit to
- Study type: Interventional
- Participants enrolled: 48
- From 1 Jul 2024 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years.
- Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)
Other illness
- Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
Other
- Highlanders who cannot follow the study investigations,
Who the study is looking for
- Permanently living \>2500 m
- HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m
- Written informed consent
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aksay Medical Center Coordinator of this site? Confirm its status | Aksay Plateau, Naryn, Kyrgyzstan | Kyrgyzstan | Unknown status |
Related publications
- Effects of high-dose supplemental oxygen therapy on pulmonary haemodynamics at 3250 m in high-altitude residents at risk for pulmonary hypertension.BMJ Open Respir Res · 2026 · PMID 42823120
This page is information, not medical advice. Discuss any trial with your doctor.